B

BillionToOne

Biotech & Life Sciences · Menlo Park, United States · Founded 2016 · IPO 2025

BillionToOne is a biotechnology startup that operates in the healthcare sector, specifically in the field of molecular diagnostics. The company's proprietary technology, known as QCT, has the ability to detect and quantify disease at a single base-pair resolution. This means it can identify the tiniest variations in our DNA, which consists of three billion letters or nucleotides. The company's primary focus is on prenatal screening and oncology testing. Their products, Northstar Select™ and Northstar Response™, are commercially available. Northstar Select™ is used to determine the most suitable first line therapy for patients, while Northstar Response™ monitors the effectiveness of the therapy. BillionToOne's business model revolves around providing these diagnostic services to healthcare providers. They generate revenue by selling their testing services to these providers, who then use the results to guide their treatment plans. The company's mission is to make molecular testing more accurate, efficient, and accessible to all. They are driven by a culture of growth, equality, and teamwork, with a strong focus on making a positive impact in healthcare. The company was founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and is comprised of a team of engineers, scientists, and industry experts who are passionate about improving healthcare through their innovative technology. Keywords: Biotechnology, Healthcare, Molecular Diagnostics, Prenatal Screening, Oncology Testing, QCT Technology, Northstar Select™, Northstar Response™, DNA Variations, Commercial Diagnostic Services.